Viramal is led by pioneers in the women’s health industry who have developed and licensed market-leading products in the fields of fertility and female sexual health. The senior management team has a successful track record of developing and commercializing innovative therapies for biotechnology companies across the United States and Europe.

Management Team and Executive Board Members

Angela Rosetti
Chairman, Board of Directors
Angela Rossetti

Angela is an experienced public and private healthcare Director with previous executive roles at Pfizer and Wyeth, where she was responsible for managing global product portfolios, each with revenues of $1B annually. Angela is currently Executive Vice President of Cell Machines, a biopharmaceutical start up developing protein therapies for rare and other diseases and serves on the board of Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics.  Prior to this, Angela was President of Ogilvy Healthworld, a healthcare communications agency whose assignments included women’s health products and had an extensive career managing other healthcare agencies, also involved in women’s health products. For six years. she was an advisor to the biopharmaceutical investment fund at Danske Bank, and has served on many non-profit boards.  Angela is also currently Adjunct Assistant Professor of Medical Ethics at New York Medical College.

Alexandra Pearce
Chief of Operations and Chief Regulatory Officer
Dr. Alexandra Pearce

Dr. Pearce brings 25 years of experience in pharmaceutical drug development and regulatory affairs to Viramal. She joined Viramal in 2016 from her position as Executive Vice President and Head of Global Regulatory Affairs for Glenmark Pharmaceuticals, an Indian-headquartered innovator and generics pharmaceutical company. Dr. Pearce also held held increasingly responsible key positions with a variety of pharmaceutical companies, including Allergan, Parke-Davis, Amgen, and Pfizer. She is currently based in the UK, but has worked in Australia, Germany and has spent over ten years working in the US, achieving roles of increasing seniority. Alex has a first degree in Cell and Molecular Biology and a PhD in protein engineering and vaccine design.

Peter Fitzwilliam
Chief Financial Officer
Peter Fitzwilliam

Peter Fitzwilliam is an experienced finance executive who has been the finance director of several public and private companies. In addition to his role as the CFO of Viramal, Mr. Fitzwilliam is currently the group finance director of Mission Marketing Group, a London Stock Exchange-listed marketing, communications and advertising firm. Previously, he was the owner and managing director of VPF London, a provider of financial advisory and management services to private and public companies. In earlier roles, Mr. Fitzwilliam was a finance director of Photo-Me International plc, the world’s leading operator of photo booths and worked in senior finance roles at The Rank Group before becoming Finance Director of UK Mail Group. In these roles he has consistently shown his ability to grow companies, both organically and through collaborations, secure financing and manage key banking and investor relationships.
Mr. Fitzwilliam holds a Bachelor of Science in Engineering Science from the University of Exeter.

Oliver Bates
Chief Executive Officer and Co-founder
Oliver Bates

Oliver Bates has served as Chief Executive Officer of Viramal and as a member of the Board of Directors since the company was founded in 2013. He has considerable experience working with early stage pharmaceutical and technology companies on mergers and acquisitions, financing and licensing transactions. Mr. Bates is currently a director at Antev Limited, a UK-based urology company with Phase II and III stage products spanning prostate cancer, benign prostate hyperplasia and endometriosis. He is a partner at Any Other Business, a management consultancy whose clients have included ValiRx, a UK-based publicly traded biotechnology company. Previously, Mr. Bates worked in Private Equity in the UK and the US, advising private equity portfolio companies on corporate finance, deal structuring and financial planning, among other services. Mr. Bates studied Physics at Imperial College London. He holds a Bachelor of Science (honors) and is an Associate of the Royal College of Science.

Finn Larsen
Chief Medical and Development Officer and Co-founder
Dr. Finn Larsen, MD

Dr. Larsen has led multiple biotechnology companies from first-in-man clinical trials through to Phase III and FDA/European Medicines Agency approval. He has over 20 years of experience overseeing clinical development, medical and regulatory affairs for an array of United States and European biopharmaceutical companies. Before joining Viramal, Dr. Larsen consulted to several biopharmaceutical companies as their Chief Medical Officer. Prior to that, he was the VP of Clinical Development at Ardana Biosciences, Chief Medical Officer at Columbia Laboratories and Chief Medical Officer at Ipsen International. During his career, Dr. Larsen has successfully negotiated acquisitions, partnering and licensing transactions, and he is also the inventor of several patents. His broad clinical and product development experience includes therapeutic fields such as endocrinology, urology, gastroenterology, hepatology, gynecology and oncology. Dr. Larsen qualified as a medical doctor from Odense University in Denmark, and practiced medicine for eighteen years before entering the pharmaceutical industry. In addition, he completed a business degree in Sales Economics from Odense University.

Non Executive Board Members

Marian Pardo
Non Executive Director
Marian Pardo

Marian Pardo is a highly-experienced investment professional, with a deep background in investment and securities analysis and the management of large and smaller capitalization corporate investment portfolios. She has had an extensive career in banking and investment management, having started her career in commercial banking at Morgan Guaranty Trust Company, the commercial banking arm of J.P.Morgan. Ms. Pardo was appointed a lending officer at 26 years old, the youngest person ever.
Ms. Pardo was ultimately responsible for a multi-million dollar loan book which doubled under her direction, handling complex loan transactions and structured financings for Fortune 500 companies. While in the commercial bank Ms. Pardo also had extensive international experience consulting for U.S. multinationals doing business with and within Europe and South America. In 1980 Ms. Pardo transferred to the investment management division of J.P. Morgan, where she became a bank and financial services analyst. In 1986, Ms. Pardo became an equity portfolio manager at J.P. Morgan, with institutional large cap equity portfolios. On October 19, 1987, she became sole manager of a $1billion large cap U.S. equity portfolio—the day of a major market correction. Ms. Pardo used the market turmoil as an opportunity to restructure the portfolio and succeeded in bringing it back to positive investment performance. Also at JP Morgan, Ms. Pardo managed the $1 billion Small Company Trust Fund for several years, besting the indices by several hundred points. Working on the success of that fund, Ms. Pardo devised and launched a mutual fund with a parallel strategy: the Pierpont Small Company Opportunity Fund, the first publically available small cap product from J.P. Morgan. During her tenure the fund grew from zero to $200,000,000. Ms. Pardo spent 20 years at JP Morgan, including time in the private client group where she managed accounts and common trust funds totaling $2 Billion. In 2003, Ms. Pardo joined Credit Suisse Asset Management fund and advised their Small Company, and Post–Venture funds. In February, 2013 Ms Pardo became a Trustee and Board Member of the Trusts for the JP Morgan Funds, a family of mutual funds, a post she still holds. Currently Ms. Pardo is Managing Director and Principal of Virtual Capital Management LLC, a financial services consulting firm. Ms. Pardo has appeared on CNBC on several occasions, including Power Lunch and is a Board Member of the Columbus Citizens Foundation and Chair of its Philanthropic Committee.

Jonathan Synett
Non Executive (Investor) Director
Jonathan Synett

Jonathan is an experienced Fund Manager, and is currently the Board Representative for the DPTI Fund where he is the Fund Manager. Previously Jonathan was the Business Manager for EasyGroup New Ventures, and Manager of investment portfolios for Ultra High Net Worth’s, investing across a variety of sectors including technology, renewables and healthcare.

Nick Thorniley
Non Executive Director
Nick Thornilley

Public company bio-tech chairman, having had a long and well-respected career in the City of London in corporate broking with small to mid-capitalized companies

Simon Holden
General Council and Company Secretary
Simon Holden

Corporate lawyer with experience in the London AIM market, Australia, Canada and United States. Partner at Lester Aldridge LLP, London responsible for corporate law.